Labcorp, a prominent provider of laboratory services, announced on Tuesday the forthcoming retirement of Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg. He will be succeeded by Julia Wang, who will assume the role of Executive Vice President and CFO on December 2, 2024.
Eisenberg will continue with Labcorp in the capacity of Special Advisor to the CEO until April 2025. This arrangement is designed to ensure a smooth transition and to support ongoing strategic initiatives at the company.
Julia Wang brings extensive global expertise in strategic and financial management spanning the diagnostics, pharmaceutical/biotech, medical device, and consumer product sectors. Her most recent role was as CFO at BeiGene, a position she took on in June 2020 after serving there as Senior Vice President for Enterprise Optimization and Deputy CFO.
Before joining BeiGene, Wang was the Senior Vice President of Global Business Finance and Corporate Planning at Alexion Pharmaceuticals. Her earlier experience includes leadership roles at Quest Diagnostics, where she served as Vice President of U.S. Regional Finance and Enterprise Commercial and as Vice President of Finance for Value Creation.
Wang's career also includes senior financial leadership positions at Johnson & Johnson across various divisions in medical devices and pharmaceuticals. Additionally, she has held roles in finance at PepsiCo, leading various initiatives.
